University of Calgary
ucalgary.caTotal trials
673
Active
169
Phase 3
55
Total enrollment
828,864
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 71 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| 0.9% Sodium Chloride | — | — | — | — | — | 1 | |
| Lidocaine Injection 2% | — | — | — | — | — | 1 | |
| Low Dose Naltrexone | — | — | — | — | — | 1 | |
| Microcrystalline cellulose | — | — | — | — | — | 1 | |
| TNFa Antagonist - Infliximab | — | — | — | — | — | 1 | |
| TNFa Antagonist - Adalimumab | — | — | — | — | — | 1 | |
| Anti-IL12/23 or anti-IL23 - Ustekinumab | — | — | — | — | — | 1 | |
| Anti-IL12/23 or anti-IL23 - Risankizumab | — | — | — | — | — | 1 | |
| Anti-integrin - Vedolizumab IV | — | — | — | — | — | 1 | |
| Anti-integrin - Vedolizumab IV and SC | — | — | — | — | — | 1 | |
| Metoprolol | — | — | — | — | 2 | ||
| Normal saline | — | — | — | 6 | |||
| Tenecteplase | — | — | — | — | 4 | ||
| Aspirin | — | — | — | — | — | 2 | |
| amiodarone | — | — | — | — | — | 2 | |
| Multi-strain probiotics | — | — | — | — | — | 1 | |
| Vedolizumab | — | — | — | — | — | 1 | |
| Vernakalant | — | — | — | — | — | 1 | |
| ondansetron 8 mg | — | — | — | — | — | 1 | |
| Low-molecular-weight heparin | — | — | — | — | — | 1 | |
| Atomoxetine Hydrochloride | — | — | — | — | — | 1 | |
| Morphine Sulfate | — | — | — | — | — | 1 | |
| Voltaren Topical Gel | — | — | — | — | — | 1 | |
| Ibuprofen Oral Suspension 100 mg/5mL | — | — | — | — | — | 1 | |
| ORA-Blend Oral Suspension | — | — | — | — | — | 1 | |
| VersaPro Cream Base for Compounding | — | — | — | — | — | 1 | |
| Ketorolac Tromethamine | — | — | — | — | 2 | ||
| Psilocybin | — | — | — | — | 3 | ||
| phage therapy | — | — | — | — | — | 2 | |
| Ondansetron | — | — | — | — | 2 | ||
| D-cycloserine | — | — | — | — | 5 | ||
| Alemtuzumab | — | — | — | — | — | 1 | |
| Sirolimus | — | — | — | — | — | 1 | |
| Rivaroxaban 10mg | — | — | — | — | — | 1 | |
| acetylsalicylic acid (ASA) 81mg Oral | — | — | — | — | — | 1 | |
| Neuromuscular Blocking Agent - Bolus Dosing | — | — | — | — | — | 1 | |
| Neuromuscular Blocking Agent - Continuous | — | — | — | — | — | 1 | |
| Ibuprofen | — | — | — | — | — | 1 | |
| Nifedipine | — | — | — | — | — | 1 | |
| CBD 100 mg OD | — | — | — | — | — | 1 |
31 more active programs hidden
Next readouts
- 2021-03
- 2024-12-31
- 2025-01
- 2025-01-01
- 2025-03
- 2025-08
- 2025-11
- 2025-11-30
- 2025-12
- 2025-12-31
Top conditions
- Stroke18
- Obesity13
- Cancer12
- Atrial Fibrillation11
- Depression10
- Asthma9
- Hypertension9
- Coronary Artery Disease7
Frequently asked questions about University of Calgary
- How many clinical trials does University of Calgary have on ClinicalTrials.gov?
- University of Calgary is listed as the lead sponsor on 673 clinical trials in ClinicalTrials.gov, 169 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Calgary's trials are in Phase 3?
- 55 of University of Calgary's trials are in Phase 3, spread across 71 active drug programs.
- What therapeutic areas does University of Calgary focus on?
- University of Calgary's most-studied conditions on ClinicalTrials.gov are Stroke, Obesity, Cancer, Atrial Fibrillation, Depression.
- When are University of Calgary's next clinical trial readouts?
- University of Calgary has 10 upcoming primary-completion readouts tracked here; the soonest is “Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects”, expected around 2021-03.